BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21943056)

  • 41. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular and molecular mechanisms of vaccine-induced protection against retroviral infections.
    Dittmer U; Hasenkrug KJ
    Curr Mol Med; 2001 Sep; 1(4):431-6. PubMed ID: 11899087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Negative selection by an endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection.
    Young GR; Ploquin MJ; Eksmond U; Wadwa M; Stoye JP; Kassiotis G
    PLoS Pathog; 2012; 8(5):e1002709. PubMed ID: 22589728
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.
    Tatsis N; Fitzgerald JC; Reyes-Sandoval A; Harris-McCoy KC; Hensley SE; Zhou D; Lin SW; Bian A; Xiang ZQ; Iparraguirre A; Lopez-Camacho C; Wherry EJ; Ertl HC
    Blood; 2007 Sep; 110(6):1916-23. PubMed ID: 17510320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3.
    Gibbert K; Francois S; Sigmund AM; Harper MS; Barrett BS; Kirchning CJ; Lu M; Santiago ML; Dittmer U
    Retrovirology; 2014 Dec; 11():126. PubMed ID: 25539593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
    Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
    PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.
    Dittmer U; Brooks DM; Hasenkrug KJ
    J Virol; 1999 May; 73(5):3753-7. PubMed ID: 10196269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.
    Lakhashe SK; Velu V; Sciaranghella G; Siddappa NB; Dipasquale JM; Hemashettar G; Yoon JK; Rasmussen RA; Yang F; Lee SJ; Montefiori DC; Novembre FJ; Villinger F; Amara RR; Kahn M; Hu SL; Li S; Li Z; Frankel FR; Robert-Guroff M; Johnson WE; Lieberman J; Ruprecht RM
    Vaccine; 2011 Aug; 29(34):5611-22. PubMed ID: 21693155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
    Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
    PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage.
    Jensen S; Steffensen MA; Jensen BA; Schlüter D; Christensen JP; Thomsen AR
    J Immunol; 2013 Oct; 191(8):4152-64. PubMed ID: 24043891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infection of B Cell Follicle-Resident Cells by Friend Retrovirus Occurs during Acute Infection and Is Maintained during Viral Persistence.
    Windmann S; Otto L; Hrycak CP; Malyshkina A; Bongard N; David P; Gunzer M; Dittmer U; Bayer W
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunodominance of Adenovirus-Derived CD8
    Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy.
    Day SL; Ramshaw IA; Ramsay AJ; Ranasinghe C
    J Immunol; 2008 Jun; 180(11):7158-66. PubMed ID: 18490714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myd88 is required for an antibody response to retroviral infection.
    Browne EP; Littman DR
    PLoS Pathog; 2009 Feb; 5(2):e1000298. PubMed ID: 19214214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.